血清尿酸在帕金森病进展过程中是否会发生变化？

Does Serum Urate Change as Parkinson's Disease Progresses?

机构信息

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, USA.

Department of Medicine, Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.

出版信息

J Parkinsons Dis. 2020;10(4):1571-1576. doi: 10.3233/JPD-202064.

DOI:10.3233/JPD-202064

PMID:32773396

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7683051/

Abstract

Higher serum urate concentration is associated with decreased risk of Parkinson's disease (PD) as well as slower disease progression, but its relationship with severity of PD remains unclear. This study investigated whether changes in serum urate concentration over 5 years were associated with disease progression assessed by MDS-UPDRS Part III score, Hoehn and Yahr stage, or DaTscan imaging. Average serum urate concentration was stable over time and change in serum urate concentration did not correlate with worsening of measures of PD progression. These results suggest that serum urate concentration is not a monitoring biomarker of PD progression in early stages.

摘要

血清尿酸浓度升高与帕金森病（PD）风险降低以及疾病进展减缓有关，但它与 PD 严重程度的关系尚不清楚。本研究旨在探讨血清尿酸浓度在 5 年内的变化是否与 MDS-UPDRS 第三部分评分、Hoehn 和 Yahr 分期或 DaTscan 成像评估的疾病进展相关。平均血清尿酸浓度随时间稳定，血清尿酸浓度的变化与 PD 进展测量指标的恶化无关。这些结果表明，血清尿酸浓度不是早期 PD 进展的监测生物标志物。